These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 10470190)
1. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors. Gebauer G; Rieger M; Jäger W; Lang N Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190 [TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors. Gebauer G; Rieger M; Jäger W; Lang N Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184 [TBL] [Abstract][Full Text] [Related]
3. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323 [TBL] [Abstract][Full Text] [Related]
4. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
5. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233 [TBL] [Abstract][Full Text] [Related]
6. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446 [TBL] [Abstract][Full Text] [Related]
7. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters-Engl C; Medl M; Ogris E; Leodolter S Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854 [TBL] [Abstract][Full Text] [Related]
9. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561 [TBL] [Abstract][Full Text] [Related]
10. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Høgdall CK; Nørgaard-Pedersen B; Mogensen O Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866 [TBL] [Abstract][Full Text] [Related]
11. [Relationship between tumor markers and clinical symptoms in ovarian cancer]. Yakushiji M; Nishimura H Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
14. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients]. Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923 [TBL] [Abstract][Full Text] [Related]
15. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21]. Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636 [TBL] [Abstract][Full Text] [Related]
17. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622 [TBL] [Abstract][Full Text] [Related]
18. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730 [TBL] [Abstract][Full Text] [Related]
19. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Camlica H; Duranyildiz D; Tas F; Yasasever V Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592 [TBL] [Abstract][Full Text] [Related]